Serine protease inhibitors serpina1 and serpina3 are down-regulated in bone marrow during hematopoietic progenitor mobilization by Winkler, Ingrid G. et al.
T
h
e
 
J
o
u
r
n
a
l
 
o
f
 
E
x
p
e
r
i
m
e
n
t
a
l
 
M
e
d
i
c
i
n
e
 
JEM © The Rockefeller University Press $8.00
Vol. 201, No. 7, April 4, 2005 1077–1088 www.jem.org/cgi/doi/10.1084/jem.20042299
 
ARTICLE
 
1077
 
Serine protease inhibitors serpina1 and 
serpina3 are down-regulated in bone marrow 
during hematopoietic progenitor mobilization
 
Ingrid G. Winkler,
 
1,2
 
 Jean Hendy,
 
1
 
 Paul Coughlin,
 
3
 
 Anita Horvath,
 
3
 
 
 
and Jean-Pierre Lévesque
 
1,2 
 
1
 
Haematopoietic Stem Cell Laboratory, Mater Medical Research Institute, South Brisbane, Queensland 4101, Australia
 
2
 
Peter MacCallum Cancer Centre, East Melbourne, Victoria 3002, Australia
 
3
 
Department of Medicine, Monash University, Box Hill Hospital, Box Hill, Victoria 3128, Australia
 
Mobilization of hematopoietic progenitor cells into the blood involves a massive release of 
neutrophil serine proteases in the bone marrow. We hypothesize that the activity of these 
neutrophil serine proteases is regulated by the expression of naturally occurring inhibitors 
(serpina1 and serpina3) produced locally within the bone marrow. We found that serpina1 
and serpina3 were transcribed in the bone marrow by many different hematopoietic cell 
populations and that a strong reduction in expression occurred both at the protein and 
mRNA levels during mobilization induced by granulocyte colony-stimulating factor or 
chemotherapy. This decreased expression was restricted to the bone marrow as serpina1 
expression was maintained in the liver, leading to no change in plasma concentrations 
during mobilization. The down-regulation of serpina1 and serpina3 during mobilization may 
contribute to a shift in the balance between serine proteases and their inhibitors, and an 
accumulation of active neutrophil serine proteases in bone marrow extravascular fluids that 
cleave and inactivate molecules essential to the retention of hematopoietic progenitor cells 
within the bone marrow. These data suggest an unexpected role for serpina1 and serpina3 in 
regulating the bone marrow hematopoietic microenvironment as well as influencing the 
migratory behavior of hematopoietic precursors.
 
Hemopoietic progenitor cells (HPCs) are re-
sponsible for the renewal of all mature blood
cells. In adult mammals, the majority of HPCs
reside in the BM. Transient increases in the
number of HPCs circulating in the peripheral
blood (mobilization) occur in response to a
wide variety of stimuli including strenuous
physical exercise, myelosuppressive chemo-
therapy, polyanions, chemokines, and hemato-
poietic growth factors (1).
Mobilized HPCs are now the favored
source of transplantable cells to reconstitute
hematopoiesis after high-dose chemotherapy.
Currently, the agent most commonly used to
elicit HPCs mobilization is G-CSF used alone
or in combination with myelosuppressive che-
motherapy (2, 3). The administration of G-CSF
induces a 10- to 100-fold increase in the level
of circulating HPCs in both humans and mice.
G-CSF–induced mobilization is time and
dose dependent, involving a rapid neutrophilia
(evident within hours) and a gradual increase
in HPC numbers in the blood peaking between
4 and 7 d of G-CSF administration. Mobilization
with chemotherapeutic agents such as cyclo-
phosphamide (CY) occurs during the recovery
phase after the chemotherapy-induced neutro-
penia, that is, days 6–8 in mice, and days 10–14
in humans. Although mobilized HPCs collected
from the peripheral blood are extensively used
to rescue hematopoiesis in patients undergoing
high-dose myeloablative chemotherapy, the ex-
act molecular mechanisms responsible for the
mobilization of HPCs from the BM into the
peripheral blood remain unclear.
Essential for the retention of HPCs in the
BM are adhesive and chemotactic interactions.
Particularly important are (a) the adhesive in-
teraction between the vascular cell adhesion
molecule VCAM-1 (CD106) expressed by
the BM stroma with its counter receptor inte-
grin 
 
 
 
4
 
 
 
1
 
 (VLA-4) expressed by HPCs, and
(b) HPC chemotaxis due to binding of the
chemokine CXCL12 (SDF-1) produced by
the BM stroma, to its cognate receptor CXCR4
(CD184) expressed at the surface of HPCs.
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Blocking either of these interactions; the VCAM-1–
 
 
 
4
 
 
 
1
 
 ad-
hesive interaction (4–6) or the CXCL12–CXCR4 chemo-
taxic interaction (7, 8), by means of antibodies, antagonists,
or tissue-specific gene-targeted deletion has been shown to
result in mobilization of HPCs in vivo
 
.
 
Our group has shown that HPC mobilization induced by
G-CSF or CY coincides with the accumulation of high con-
centrations of active neutrophil serine proteases within the
BM (9, 10). The predominant proteases were identified as
neutrophil elastase (NE) and cathepsin G (CG), both re-
leased by neutrophils upon activation (9, 10). Once released
into the BM extracellular fluid, these proteases can disrupt
locally the two important mechanisms by which HPCs
home to and remain within the BM: (a) adhesion to the BM
stroma by cleaving the extracellular domain of VCAM-1 (9,
10), and (b) chemotaxis of HPCs by degrading and inactivat-
ing the chemokine CXCL12 (11, 12) and cleaving the 1st
extracellular domain of CXCR4 expressed by human HPCs
(12). As previous studies have shown, inactivation of either is
sufficient to induce mobilization. However, a mechanism
explaining how high concentrations of active neutrophil
serine proteases accumulate in the BM during mobilization
remains unclear.
Neutrophil serine protease activity is controlled in vivo
by naturally occurring serine protease inhibitors or serpins
(13, 14). Serpins function like mousetraps with a protruding
reactive center loop. Cleavage of this reactive center loop
by a specific protease triggers a spring-like mechanism,
which entraps the protease within the serpin structure de-
stroying the protease catalytic architecture (15–17). Once
formed, the inactive serpin–protease complex is rapidly
cleared from the body. Although serpin structure is very
conserved, the reactive center loop sequence is highly vari-
able between different serpins allowing the targeting of spe-
cific proteases. Two groups of serpins located on chromo-
some 14 in humans and chromosome 12 in mice (referred
to as “clade A” serpins; 14, 18) can inactivate neutrophil
serine proteases in blood and tissues. These are SERPINA1
(also known as 
 
 
 
1
 
-proteinase inhibitor or 
 
 
 
1
 
-antitrypsin: AAT)
and SERPINA3 (
 
 
 
1
 
-antichymotrypsin: ACT; 19, 20). Al-
though humans express a single copy of each 
 
SERPINA1
 
and 
 
SERPINA3
 
 gene, in the house mouse 
 
Mus musculus
 
the 
 
serpina1
 
 gene has replicated five times (
 
serpina1a–e
 
; 21–
23) whereas the 
 
serpina3
 
 gene has replicated 14 times
(
 
serpina3a–n
 
; 23, 24).
To explain how high concentrations of active neutrophil
serine proteases accumulate in the bone marrow during HPC
mobilization, we hypothesize that (a) serine protease inhibi-
tors, in particular serpins, are present in steady-state BM pre-
venting the action of serine proteases released by BM neu-
trophils in steady-state conditions, and (b) that the balance
between serine proteases and their inhibitors shifts in mobi-
lized BM leading to the accumulation of active NE and CG.
Herein we report that, serpina1 and serpina3 are both
transcribed in steady-state BM and are present at sufficient
concentrations to inhibit local serine proteases. During mo-
bilization induced by either G-CSF or CY, both protein and
mRNA concentrations of serpina1 and serpina3 in the BM
dramatically drop associated with an accumulation of active
neutrophil serine proteases and concomitant cleavage and in-
activation of molecules essential for the retention of HPCs
within the BM.
 
RESULTS
Inhibitors of serine proteases are present in steady-state BM 
extracellular fluids
 
We have reported previously a dramatic increase in active
serine protease levels in the BM at the peak of mobilization
induced either by G-CSF or CY (9, 10, 12). This could be
due to (a) a corresponding increase in protease production/
release, and/or (b) a drop in the level of inhibitors that con-
trol the activity of these proteases. To determine whether nat-
urally occurring protease inhibitors are involved in the regula-
tion of protease activity in the BM, recombinant VCAM-1
was incubated with pooled BM fluids from three saline-
injected mice (Fig. 1, lane 1), three G-CSF day 4 mice (lane
3), or a mixture of the two (lane 2). As expected from our
previous work, no cleavage of VCAM-1 was observed when
incubated with BM fluids from saline-injected nonmobilized
mice, whereas cleavage of VCAM-1 did occur when incu-
bated with BM fluids from G-CSF day 4 mice (9, 10). Inter-
estingly, when both BM fluids were mixed together (lane 2)
cleavage was significantly reduced. This result demonstrates
that naturally occurring protease inhibitors are present in the
BM fluids from steady-state (saline-injected) mice in sufficient
quantities to significantly inhibit the proteolytic activity of
BM fluids from mice mobilized with G-CSF.
When these same pooled BM fluids from G-CSF day 4
mice were incubated with purified human SERPINA1 (
 
 
 
1
 
-
antitrypsin), complete inhibition of VCAM-1 cleavage was
Figure 1. Extracellular fluids from steady-state BM contain serine 
protease inhibitors whereas those from mobilized BM do not. Extra-
cellular fluids from the BM of G-CSF–mobilized mice were mixed with an 
equal volume of PBS or extracellular fluids from saline-injected mice or 
with purified human SERPINA1, BB-94, or O-phenantroline as indicated. 
The proteolytic activity of each sample was estimated by cleavage of re-
combinant human VCAM-1 visualized after immunoblotting with a goat 
anti–human VCAM-1 antibody. 
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observed, suggesting that murine steady-state BM may con-
tain similar serine protease inhibitors (Fig. 1, compare lanes
1, 3, and 4). Inhibitors of matrix metalloproteinases such as
BB-94 (Fig. 1, lane 5) or O-phenanthroline (lane 6) did not
prevent VCAM-1 cleavage. Together these results indicate
that the proteases in G-CSF–mobilized murine BM fluids
able to cleave VCAM-1 are predominately serine proteases
(inhibited by SERPINA1) and not matrix metalloprotein-
ases. Consequently, the inhibition of protease activity by
steady-state BM fluids is not due to tissue inhibitors of me-
talloproteinases but rather to endogenous serpins or nonser-
pin inhibitors of serine proteases.
 
Levels of serpina1 protein drop in the BM 
during mobilization
 
Serpina1 protein, the main inhibitor of NE in tissues, was
analyzed in BM extracellular fluids by immunoblotting.
Whereas serpina1 (53 kD) was present in BM fluids before
and after mobilization, levels were significantly decreased
during HPC mobilization on days 2–6 after G-CSF adminis-
tration (Fig. 2 A). Similarly, levels of serpina1 were signifi-
cantly decreased in the BM fluids from CY-treated mice
between days 6–10 again corresponding to the peak of
mobilization in these mice (Fig. 2 B). This decrease in
serpina1 was restricted to the BM as no corresponding
Figure 2. Concentration of serpina1 protein in BM extracellular 
fluids drops during mobilization induced by G-CSF or CY. Aliquots of 
BM extracellular fluids or blood plasma were taken at indicated time-
points of mobilization induced by G-CSF (A) or by CY (B) and analyzed by 
immunoblotting with a rabbit anti–human SERPINA1 cross-reacting with 
mouse serpina1. The 53-kD intact, 50-kD cleaved, and 76-kD complexed 
forms of serpina1 are indicated by arrows as determined in Fig. 3 A. Panels 
C and D show the concentration of serpina1 ( ), active NE ( ), and CG 
( ) in BM extracellular fluids from G-CSF– (C) and CY-mobilized (D) mice. 
Results are expressed in picomoles per femur. Values are mean   SD of 
three mice per time-point. E shows a calibration curve for the quantifica-
tion of serpina1 protein. Serial dilutions of mouse plasma were immuno-
blotted with serpina1 antibody and fluorescent intensity of the 53-kD 
serpina1 band measured using the Odyssey Infrared Imaging System. F 
shows the same CY-mobilized BM extracellular fluids and plasma as B, but 
immunoblotted with rabbit anti–human  2-macroglobulin. 
SERPINS IN HEMATOPOIESIS | Winkler et al.
 
1080
 
change in serpina1 was observed in the matching plasma
from these same mice (Fig. 2, A and B, lower panels).
Interestingly, a large increase in serpina1 was observed
specifically on day 3 after CY injection. As the BM is very
damaged at this time-point, we hypothesized that this peak
in serpina1 in the BM could be due to blood infiltration
across the endothelium into the BM. This was confirmed by
immunoblotting the same BM fluids as above for 
 
 
 
2
 
-macro-
globulin, a major plasma protein. Because of its large size
(four 160-kD subunits linked by disulfide bridges), 
 
 
 
2
 
-mac-
roglobulin cannot normally diffuse through vascular walls
from the blood into tissues. Although 
 
 
 
2
 
-macroglobulin was
readily detected in all blood samples, it was only detected in
the BM extravascular fluids of mice at day 3 after CY admin-
istration, but absent from all other BM fluids (Fig. 2 F).
In another series of experiments, serpina1 concentration in
BM fluids from individual mice were directly measured from
immunoblots using a secondary antibody conjugated to the
infrared fluorescent dye Alexa Fluor 680 and the Odyssey In-
frared Imaging System. The advantage of this system is that
the fluorescent intensity of a band is directly proportional to
serpina1 concentration (Fig. 2 E, see standard curve). Large
amounts of serpina1 (54.3 
 
 
 
 1.3 picomole [2.9 
 
 
 
g]/femur)
were measured in steady-state BM fluids (Fig. 2 C), dropping
to 11.0 
 
 
 
 1.2 picomole [0.5 
 
 
 
g]/femur on day 6 of G-CSF
mobilization and rebounding (to 185 
 
 
 
 49 picomole [9.8
 
 
 
g]/femur) during the recovery from mobilization. A similar
drop in serpina1 concentration (down to 5.1–7.6 picomole/
femur) was observed in the BM of CY-mobilized mice at days
6–10 during mobilization, with serpina1 levels again rebound-
ing to 61–66 picomole/femur on days 12–14 (Fig. 2 D).
As no specific antibodies for murine NE and CG are
available, it was not possible to directly measure changes in
protease concentration during mobilization. Instead we
measured proteolytic activity using specific chromogenic
substrates and then calculated the molar concentration of
each within a femur using purified human NE and CG as
standards (Fig. 2, C and D). As serpina1 inhibits both NE
and CG with a 1:1 stoichiometry (19, 20), the concentration
of serpina1 (53 kD) in steady-state BM fluids is sufficient to
inhibit all NE and CG present in a steady-state femur. How-
ever, at the peak of mobilization, serpina1 decreases and ac-
tive NE and CG in the BM are in large molar excess (up to
45 times over serpina1 on day 6 of G-CSF and 36 times on
day 6 after CY injection).
Serpina1 within the BM may originate from two possible
sources. It may derive from blood slowly diffusing through
the BM endothelium into the BM extracellular fluid, or al-
ternatively, serpina1 may be endogenously produced by BM
cells. If continuous diffusion from blood was the predomi-
nant source of BM serpina1, it is likely that this process
would continue during mobilization with the “fresh”
serpina1 being continuously cleaved and complexed by the
increased active neutrophil serine proteases. This would re-
sult in the accumulation of cleaved and complexed serpina1
in the BM fluid. Alternatively, a decrease in endogenous
production of serpina1 by BM cells during mobilization
would also result in the observed decrease in intact serpina1
levels within the BM fluid but without an associated increase
in cleaved or complexed serpina1 forms.
We first confirmed the identity of the 50- and 76-kD
bands detected on previous blots (Fig. 2, A and B), by incu-
bating mouse plasma with increasing concentrations of NE
for 30 min at 37
 
 
 
C (Fig. 3 A). Indeed the 53-kD “intact”
serpina1 band disappeared when incubated with increasing
concentrations of NE, with a concurrent 3.5-fold increase in
the 50-kD band (cleaved serpina1) and sixfold increase in the
76-kD band (complexed serpina1). The concentration of 50-
kD cleaved and 76-kD complexed serpina1 bands were then
quantified in BM extracellular fluids from G-CSF– and CY-
mobilized mice (Fig. 3 B). This quantification revealed that
the concentration of cleaved and complexed serpina1 did not
increase in BM extracellular fluids during mobilization sug-
gesting that serpina1 diffusion from the blood through the
BM endothelium is limited and below the rate required to
replenish the pool of intact serpina1 cleaved by NE and CG
released by BM neutrophils. This conclusion is supported by
the fact that when the endothelium barrier is disrupted at day 3
after CY injection (Fig. 2, B and D), serpina1 diffusion into
the BM extracellular fluid dramatically rises resulting in an
11.5-fold increased serpina1 concentration compared with
nonmobilized mice. Taken together, these data indicate that
serpina1 diffusion through the BM endothelial barrier is lim-
ited and endogenous production within the BM is likely to
Figure 3. Relative variations in intact serpina1, cleaved serpina1, 
and serpina1–protease complexes during mobilization. (A) Mouse 
plasma was incubated with increasing concentrations of purified human 
NE and then immunoblotted with rabbit anti-SERPINA1 to reveal the dis-
appearance of intact 53-kD serpina1 and appearance of cleaved 50-kD 
and complexed 76-kD serpina1 band in the presence of excess serine pro-
tease. The relative intensities of 50-, 53-, and 76-kD bands were measured 
using the Odyssey Infrared Imaging System. (B) BM extracellular fluids 
were taken from mice mobilized with G-CSF or CY at indicated time-
points and then immunoblotted and the relative intensities of the 50, 53, 
and 76-kD serpina1 bands measured as described above. Values from non-
mobilized control mice were used to calculate the 100% baseline. 
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be the predominant contributor to the large amounts of
serpina1 observed within BM.
 
Reduction of serpina1a–e mRNA levels in the BM 
during mobilization
 
To further investigate endogenous BM production of
serpina1, total RNA was extracted from BM cells of six indi-
vidual mice injected with either saline for 4 d, G-CSF for
4 d, or 8 d after a single injection of CY, and quantitative
real-time RT-PCR performed. Results were standardized
using primers specific for murine vimentin, a cytoskeleton
protein ubiquitously expressed.
Using primers that amplify transcripts from the five mu-
rine 
 
serpina1
 
 genes (
 
serpina1a–e
 
), we observed a dramatic de-
crease in serpina1a–e mRNA levels in the BM of mice mo-
bilized with G-CSF (8,000-fold decrease) or CY (790-fold
decrease; Fig. 4 A). When primers to 
 
 
 
2
 
-microglobulin
(
 
 
 
2
 
m), another ubiquitously expressed gene, were substi-
tuted for the pan-serpina1 primers, there was no difference
between saline-, G-CSF–, or CY-injected mice. These re-
sults confirm that 
 
serpina1
 
 genes are transcribed in the BM,
and that the concentration of transcripts decreases during
mobilization. Furthermore, the decrease in concentration of
mouse serpina1a–e transcripts is specific (no changes are
found with other RNAs such as 
 
 
 
2
 
m) when compared with
the vimentin.
To confirm real-time RT-PCR results, a repeat PCR
was stopped at 30 cycles for serpina1 (mid-log phase of reac-
tion) or 25 cycles for 
 
 
 
2
 
m, run on 8% PAGE and bands visu-
alized with ethidium bromide. After 30 cycles, serpina1
product (140 bp) was detectable in RNA from the BM of
three individual saline-injected mice but not in the three
G-CSF–mobilized mice (Fig. 4 B).
Real-time RT-PCR was performed from BM at differ-
ent time-points of G-CSF–induced mobilization. The de-
crease in serpina1 mRNA on days 2, 4, and 6 (Fig. 4 C) cor-
responds to the timing of decreased serpina1 protein in BM
fluids (Fig. 2) as well as the rise in colony-forming cells mo-
bilized into the peripheral blood (Fig. 4 E).
Similar decreases in serpina1a–e mRNA levels were
observed in the BM at the peak of CY-induced mobiliza-
tion (days 6–8). Together these data indicate that a signifi-
cant two to three log decrease in serpina1a–e mRNA con-
centration occurs in the BM at the peak of mobilization
even when two completely different mobilization proto-
cols (either G-CSF, a cytokine, or CY, a cytotoxic agent)
are used.
 
Transcription of the neutrophil proteases NE, CG, as well as 
VCAM-1 and CXCR4 in the BM remains unchanged 
during mobilization
 
In sharp contrast to serpina1, no significant change in NE or
CG transcripts was observed during mobilization induced by
G-CSF or CY (Fig. 4 D and Fig. 5). However this is not
surprising as these two proteases are transcribed in myeloid
progenitors (see Fig. 6 E and reference 25) and stored in
Figure 4. Reduced serpina1 mRNA levels in the BM during mobili-
zation induced by G-CSF or CY. (A) Total RNA was isolated from BM 
cells of mice injected for 4 d with saline (Sal), G-CSF (G), or 8 d after a single 
cyclophosphamide injection (Cy). Murine serpina1a–e (left) and  2m 
mRNA levels were measured by quantitative real-time RT-PCR. Results are 
expressed as mRNA amount relative to mRNA for the cellular cytoskeleton 
protein vimentin (on a log scale). Each symbol represents the mRNA level 
from a different mouse. Black bars represent average of each group. 
(B) RNA was extracted from the BM cells of six mice injected with saline or 
G-CSF for 4 d. Products after RT-PCR for serpina1a–e (30 cycles) or  2m 
(25 cycles) were loaded on 8% PAGE and visualized by ethidium bromide 
staining. (C) Kinetics of serpina1 mRNA levels during the course of G-CSF– 
(left) and CY-induced (right) mobilization. Concentrations of serpina1 
mRNA were measured by real-time RT-PCR from whole BM cells and are 
relative to vimentin mRNA. Data are mean   SD of six to nine mice per 
time-point. (D) Kinetics of NE mRNA levels during the course of G-CSF–
induced (left) and CY-induced (right) mobilization. Concentrations of 
mRNA were measured as described in C. (E) Kinetics of CFC mobilization 
into the peripheral blood induced by G-CSF (left) and CY (right). Data are 
mean   SD of six to nine mice per time-point. 
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azurophil granules where they are released upon granulocyte
activation (26) or in response to mobilizing agents (27).
No significant changes in the transcription of other mol-
ecules reported to be important for the retention of HPCs in
the BM such as VCAM-1 or CXCR4 were observed (Fig.
5). Taken together, these results support the notion that a
significant drop in serpin production combined with neutro-
phil activation and degranulation (27), both contribute to
the increased active serine protease levels observed in mouse
BM at the peak of G-CSF– and CY-induced mobilization.
 
Serpina3 mRNA decreases in the BM at the peak 
of mobilization
 
Using the same approach, we followed the mRNA levels of
six murine 
 
serpina3
 
 genes that encode serpins with an NH
 
2
 
-
terminal secretion sequence and thus are potentially secreted
by cells (
 
serpina3b
 
, 
 
serpina3c
 
,
 
 serpina3d
 
, 
 
serpina3k
 
,
 
 serpina3m
 
, and
 
serpina3n
 
; 23). A similar decrease in transcripts (between 8-
and 1,400-fold) was found in the BM at the peak of mobiliza-
tion induced by either G-CSF or CY (Fig. 5, bottom) with
the exception of 
 
serpina3b,
 
 which was not transcribed in the
BM of BALB/c mice. We also analyzed by real-time RT-
PCR, transcripts of another five murine 
 
serpina3
 
 genes that
have no secretion sequences and are thus presumed to re-
main cytoplasmic (
 
serpina3e
 
, 
 
serpina3f
 
,
 
 serpina3g
 
,
 
 serpina3h
 
, and
 
serpina3i
 
), the majority of which were detected in the BM of
steady-state BALB/c mice (Table I). Similar to the secreted
serpina3, the mRNA levels of these other 
 
serpina3
 
 genes were
significantly decreased at the peak of mobilization (-fold re-
duction in BM transcription at day 4 of G-CSF was 85 with
P 
 
  
 
0.001 for 
 
serpina3e
 
 and 
 
serpina3i
 
, 621 with P 
 
  
 
0.01 for
 
serpina3g
 
, and 1,592 with P 
 
  
 
0.01 for 
 
serpina3h
 
). 
 
Serpina3f
 
was not expressed in steady-state or mobilized BALB/c BM.
 
Decrease in serpina1 and serpina3 transcripts within sorted 
BM cell populations during mobilization
 
The exact identity of cell types expressing serpina1 and serpina3
in mouse BM has not been thoroughly investigated. We sorted
BM cells from saline- and G-CSF–treated mice at day 4 based
on lineage markers to determine which cell types were express-
ing serpina1 and serpina3 and whether serpin transcription in
these cells was down-regulated during mobilization.
We first examined myeloid cells as they are the predomi-
nant cell type accumulating in the BM at the peak of mobili-
zation (Fig. 6 A). Bone marrow myeloid cells were sorted on
the basis of positive CD11b (Mac-1) expression and relative
maturity on the basis of Gr-1 expression (Fig. 6, B and C)
with primitive-mono/myeloid cells being Gr-1
 
dim
 
 (sort gate
R3), immature myeloid intermediate for Gr-1 staining (sort
gate R4), and mature BM neutrophils Gr-1
 
bright
 
 (sort gate
R2). With G-CSF–induced mobilization a twofold increase
in both the proportion and total cell number of primitive
Mac-1
 
 
 
Gr-1
 
dim/intermediate
 
 myeloid cells (R3 plus R4 regions)
was found in the BM.
By real-time RT-PCR, serpina1a–e mRNA transcripts
were greatest in BM neutrophils (Mac-1
 
 
 
 Gr-1
 
bright
 
) with
one or two log less mRNA in more primitive Gr-1
 
intermediate
 
and Gr-1
 
dim
 
 cells, respectively (Fig. 6 D). Importantly, at the
peak of G-CSF mobilization, a dramatic and significant tran-
scriptional down-regulation of 
 
serpina1a–e
 
 genes was ob-
served when compared with saline-injected BM in all mye-
loid subsets. This transcriptional down-regulation was not
just specific to serpina1a–e genes, but was also found with the
secreted  1-antichymotrypsin serpina3c (mRNA concentra-
tion was 5-fold lower in BM neutrophils and 10-fold lower
in more primitive myeloid cells) during mobilization. How-
ever, no change was found for other mRNAs transcribed by
these cells during mobilization. For example, although tran-
scription of the protease CG is higher in more primitive
myeloid cells than in mature BM neutrophils (consistent
with packaging in primary azurophil granules), administra-
tion of G-CSF was not found to alter CG transcript levels in
any of the three myeloid cell populations sorted from the
BM (Fig. 6 E).
A similar 100–1,000-fold decrease in serpina1a–e mRNA
levels was also observed during mobilization for other sorted
BM cell populations such as B220  B lymphocytes, CD4 
Figure 5. mRNA levels of secreted murine serpina3, NE, CG, VCAM-1, 
and CXCR4 at the peak of HPC mobilization induced by G-CSF or 
CY. mRNA levels were measured by real-time RT-PCR from BM cells iso-
lated from mice injected for 4 d with saline (Sal) or G-CSF (G) or at day 6 
after a single CY injection (Cy). Results are expressed as mRNA level rela-
tive to mRNA for the cytoskeleton protein vimentin (on a log scale). Each 
symbol represents the mRNA level from a different mouse. Black bars 
represent average of each group. Fold decreases between saline-treated 
groups and G-CSF– or CY-treated groups, together with corresponding 
significance levels (*, P   0.05; **, P   0.01 and NS for nonsignificant) are 
indicated underneath.JEM VOL. 201, April 4, 2005 1083
ARTICLE
and CD8  T lymphocytes, and total CD45  hematopoietic
cells (unpublished results).
Decreases in serpina1 transcripts is restricted to the BM of 
mobilized mice
During mobilization, a large number of the mobilized
HPCs home to the spleen. We therefore queried whether
the drop in serpina1 and serpina3 transcripts during mobili-
zation was a general phenomenon or restricted to the BM.
For this purpose, we analyzed serpina1 mRNA levels in
liver, BM, and spleen by real-time RT-PCR and con-
firmed these results at the protein level by immunohis-
tochemistry of tissue sections.
SERPINA1 and SERPINA3 proteins are present in the
blood at high concentrations at 1.5 and 0.5 mg/ml, respec-
tively, in humans (28). They are mainly produced by the
liver and released into the blood. The regulation of expres-
sion has not been exhaustively studied in the mouse. As ex-
pected, we found high levels of serpina1a–e mRNAs (Fig. 7
A, left) and serpina1 protein expression (Fig. 7 B, left) in liver
cells, with no change in mRNA or protein expression during
G-CSF–induced mobilization. Conversely, serpina1a–e tran-
scripts dropped dramatically (1,000-fold) in mouse BM dur-
ing G-CSF–induced mobilization (Fig. 7 A) with a corre-
sponding sharp drop in protein levels (Fig. 7 B, middle).
Interestingly, although serpina1a–e transcription in the
spleen of mice was minimal, it increased during mobilization
(Fig. 7 A). This finding was confirmed at the protein level by
immunohistochemistry showing accumulation of cell clusters
producing serpina1 proteins within the myeloid areas of the
Table I. Murine serpin genes and primer sequences
Old nomenclature
Sequence of reactive 
loop, P1P1’
NH2-terminal 
secretion sequence
Oligonucleotide sequences for real-
time RT-PCR
RT-PCR 
BALB/c BM
Serpina1
Serpina1a Spi1-1 MSa Yes f 5 -gaagctgcagcagctacagtc-3 
5 -tgtgggatctaccacttttcc-3 
 
Serpina1b Spi1-2 MSa Yes “ “
Serpina1c Spi1-3 YS Yes “ “
Serpina1d Spi1-4 YS Yes “ “
Serpina1e Spi1-5 LSb Yes “ “
Serpina3
Serpina3a Unknown1 QS Yes ND
Serpina3b 6A1 MSa Yes f 5 -TCATGTCTGCAAAACTTAAAC-3 
5 -TGTGGGGTTGATAACCTTTCC-3 
 c
Serpina3c 1A1 LSb Yes f 5 -CTTAGTAGAAGAACCAGTCTG-3 
5 -CTTAGGGTGAGTGATTTTGGC-3 
 
Serpina3d 2B1 LSb Yes f 5 -AGATTCAAAATTGCCCCACTG-3 
5 -CTTGGGATTCAAGACTTTCAC-3 
 
Serpina3e 2B2(b) RC ? f 5 -AGGAGTTAAAGTTAATCTACG-3 
5 -CTTGGGATTTGTAACTTTGGC-3 
 d
Serpina3f 2A1 CC No f 5 -ATCTCCAATGTTGTCAAGGTG-3 
5 -TG(T/G)AACTTTTGCCATAAAGAG-3 
 c
Serpina3g 2A2 CC No f 5 -CAGGAATGGCAGGTGTCGG-3 
5 -TG(T/G)AACTTTTGCCATAAAGAG-3 
 c
Serpina3h 6C28 CC No f 5 -CCACAGGGGTCAAATTAATTC-3 
5 -CTTGGGATTTGTAACTTTGGC-3 
 
Serpina3i 2B2 RC No f 5 -AGGAGTTAAAGTTAATCTACG-3 
5 -CTTGGGATTTGTAACTTTGGC-3 
 d
Serpina3j Unknown2 LSb Yes ND
Serpina3k MMCM RK Yes f 5 -GTTATTGGTGGCATTCGTAAG-3 
5 -CTTGGGGTTA(T/G)TGACTTTGGC-3 
 
Serpina3l 3E2 QS Yes ND
Serpina3m 3e46 RS Yes f 5 -GCTTTCGTTCTAGAAGATTAC-3 
5 -CTTGGGGTTA(T/G)TGACTTTGGC-3 
 c
Serpina3n EB22.4 MSa Yes f 5 -CAATGTCTGCGAAACTGTACC-3 
5 -TTTGGGGTTGGCTATCTTGGC-3 
 
a”MS” is the canonical human  1-antitrypsin–reactive center loop P1P1’.
b”LS” is the canonical human  1-antichymotrypsin–reactive center loop P1P1’.
cDenotes that PCR was performed with a lower annealing temperature of 55 C.
dOligonucleotides for serpina3e and serpina3i do not distinguish between these two transcripts.SERPINS IN HEMATOPOIESIS | Winkler et al. 1084
spleen from mobilized mice but barely detectable in the
spleens from nonmobilized mice. However, no increase in
serpina1a–e mRNA was found in Gr-1  cells sorted from
spleens of mobilized versus nonmobilized mice (unpublished
results) suggesting that the increase in serpina1 protein and
mRNA levels in the spleen after the administration of
G-CSF is most likely due to the migration of serpin-produc-
ing cells (such as myeloid cells) from the BM into the spleen.
This is supported by the findings that the spleen of saline-
injected mice contained 6   2% Gr-1  neutrophils increasing
to 25   5% Gr-1  neutrophils after 4 d of G-CSF. When
absolute numbers are considered, this corresponds to 5   2  
106 neutrophils/spleen in nonmobilized animals compared
with 38   7   106 neutrophils/spleen with mobilization.
RT-PCRs using primers for serpina3c revealed a similar
phenomenon, that is a drop in mRNA levels in the BM and
increased mRNA concentrations in spleen during mobiliza-
tion (Fig. 7 A, right). In the liver, mobilization also resulted
in a 10-fold decrease in serpina3c transcripts.
DISCUSSION
In this paper we report that steady-state BM contains a molar
excess of serpina1 compared with the serine proteases NE and
CG. As serpins irreversibly block serine proteases with 1:1 stoi-
chiometry (19, 20), this concentration of serpina1 is sufficient
to inhibit neutrophil serine proteases released in steady-state
BM. Furthermore, we report that mobilization is associated
with a sharp drop in the concentration of both serpina1 protein
and mRNA levels in the BM, which may contribute to the ac-
cumulation of active NE and CG within this tissue. The de-
crease in intact 53-kD serpina1 protein in mobilized BM was
not accompanied by a rise in serpina1–protease complexes
nor in cleaved serpina1 levels, which normally occurs when
serpina1 is cleaved by serine proteases. Therefore our data sug-
gests that the decrease in transcription of endogenous serpina1
in mobilized BM was not compensated by liver-derived
serpina1 diffusion from the blood. Taken together, these data
support the hypothesis that the rise in NE and CG proteolytic
activity in the BM during mobilization is likely to be due to
the dual effects of both an increase in neutrophil activation as
well as a decrease in the replenishment of serine protease inhib-
itors such as serpina1 and serpina3. Furthermore after stopping
G-CSF treatment, a rebound in serpina1 and serpina3 mRNA
and protein levels in the BM is observed possibly contributing
to the cessation of mobilization. Of note, we have also found
similar results in other inbred mouse strains such as C57BL6/J,
C3H/HEJ, and 129SvJ confirming that this phenomenon is
not restricted to a particular mouse strain (unpublished results).
Figure 6. Serpina1 transcripts are decreased in all BM mono/myeloid 
populations during HPC mobilization. (A) Number of nucleated cells 
and Mac-1  (CD11b ) mono/myeloid cells in the femoral BM during the 
course of G-CSF administration. Data represent mean   SD from six to 
nine mice per group. (B) Phenotypic expression and sorting of primitive 
mono/myeloid Mac-1  Gr-1dim cells (gate R3), immature myeloid Mac-1  
Gr-1intermediate cells (gate R4), and mature Mac-1  Gr-1bright neutrophils 
(gate R2) from mouse BM after 4 d of saline (left) or G-CSF (right) injec-
tion. Percentages in sorting gates indicate the proportion of these cells 
among total BM-nucleated cells. (C) Giemsa staining of the R3, R4, and R2 
populations sorted as above. Top row corresponds to cells sorted from BM 
of saline-injected mice whereas the bottom row corresponds to cells 
sorted from the BM of G-CSF–injected mice. (D) Serpina1 mRNA expression 
levels in R3, R4, and R2 populations sorted from the BM of mice injected 
for 4 d with saline (gray columns) or G-CSF (white columns). Results are 
expressed as mRNA concentration relative to vimentin mRNA on a log 
scale. (E) Cathepsin G (CG) mRNA expression levels in R3, R4, and R2 pop-
ulations sorted from the BM of mice injected for 4 d with saline (gray col-
umns) or G-CSF (white columns). Results are expressed as mRNA concen-
tration relative to vimentin mRNA on a log scale.JEM VOL. 201, April 4, 2005 1085
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Interestingly, hepatic transcription of serpina1 was not al-
tered during HPC mobilization, resulting in constant blood
plasma levels. This would explain in part why there is no ac-
tive NE or CG in the blood and no cleavage of VCAM-1 on
the lumen of BM sinuses that are in direct contact with
blood (9). VCAM-1 expression in the spleen does not
change during mobilization (9). In this study using immuno-
histochemistry as well as real-time RT-PCR, we show that
cells producing serpina1 proteins accumulate in the spleen
during mobilization, possibly protecting VCAM-1 from pro-
teolytic cleavage by neutrophil serine proteases in this tissue.
The human genome has only one copy of the SER-
PINA1 and SERPINA3 genes and their target protease
specificity is well established (29). Both human SERPINA1
and SERPINA3 proteins can inhibit NE and CG in vitro,
however human SERPINA1 preferentially targets NE (with
the reactive center loop P1P1
  amino acids “MS”; 19) whereas
SERPINA3 preferentially targets CG (with reactive center
loop P1P1
  amino acids “LS”; 20). The reactive center loop
of many of the murine serpina1 and serpina3 proteins have
diverged (30), although several still exhibit the canonical  1-
antitrypsin reactive center loop (murine serpina1a, serpina1b,
serpina3b, and serpina3n) whereas others have the canonical
 1-antichymotrypsin–reactive center loop (murine serpina1e,
serpina3c, serpina3d, and serpina3j; Table I). Therefore
members of both the murine serpina1 and serpina3 families
are likely to be involved in the inhibition of serine protease
activity in steady-state BM as shown in Fig. 1.
An interesting finding of this study is that although the
level of serpina1a–e transcripts dropped dramatically in the
BM of mice during mobilization, hepatic mRNA levels did
not alter resulting in no changes in plasma serpina1 concentra-
tions. Earlier studies on human SERPINA1 transcription/ex-
pression reveal five alternative transcription starts can be used
depending on the tissue in which expression occurs (with
three transcription start sites in leukocytes, one in cornea and
one in hepatocytes; 31). In this study we found the reduction
in serpina1 transcripts was specific to BM leukocytes during
Figure 7. Down-regulation of serpina1 is restricted to the BM dur-
ing HPC mobilization. (A) Serpina1a–e (left) and serpina3c (right) mRNA 
levels were measured in liver, whole BM, and spleen cells from mice injected 
for 4 d with saline (gray columns) or G-CSF (white columns). Results are ex-
pressed as mRNA concentration relative to vimentin mRNA on a log scale. 
(B) Immunohistochemical staining of liver, BM, and spleen sections with a 
rabbit anti–human SERPINA1 antibody cross-reacting with mouse serpina1. 
In the top row are sections from mice injected for 4 d with saline whereas in 
the bottom row are sections from mice injected for 4 d with G-CSF. The 
small inserts shown in the liver sections are negative controls performed 
with nonimmune control rabbit IgG used at the same concentration as the 
rabbit anti–human SERPINA1. All sections are magnified  200.SERPINS IN HEMATOPOIESIS | Winkler et al. 1086
mobilization whereas hepatic transcription remained un-
changed. Although we cannot exclude mechanisms involving
mRNA destabilization, this suggests that different tissue-spe-
cific serpina1 transcriptional start sites are used by murine leu-
kocyte and/or hepatic cells. In contrast to SERPINA1, the
human SERPINA3 gene appears to use a single promoter re-
gardless of tissue-type in which it is expressed (31).
Both human SERPINA1 and SERPINA3 genes are re-
ported to be “acute phase proteins” as expression increases
two- to fivefold in the liver during inflammation leading to
increased levels of SERPINA1 and SERPINA3 proteins in
plasma (32, 33). Whether a similar increase in the transcrip-
tion of hepatic murine serpina1 occurs during inflammation
remains controversial (34, 35). A few studies have reported
that several cytokines (such as IL-6, IL-1 , or TNF- ) in-
crease SERPINA1 transcription in human monocytes (36,
37). However, to our knowledge, no down-regulation of
human or mouse SERPINA1 or SERPINA3 in response to
cytokines/growth factors has been reported previously in
leukocytes or even hepatocytes.
An intriguing finding of this study is that the same murine
BM Gr-1  myeloid cells contain large amounts of serine pro-
teases as well as large amounts of serine protease inhibitors,
which would suggest that the serpins and proteases, although
present in the same cells, are stored in different compart-
ments. This is likely to be the case as serpina1 transcription is
greatest in BM neutrophils, whereas serine protease (NE and
CG) transcription was highest in primitive mono/myeloid
cells (Fig. 6). It is known that in granulocyte precursors, the
timing of transcription determines in which granules the pro-
tein products are stored (25, 38). For instance, the serine pro-
teases synthesized by primitive myeloid cells are packaged
predominantly in primary azurophil granules, whereas gran-
ule proteins synthesized by more mature BM neutrophils are
more likely packaged in secondary or tertiary granules (39).
The release of these distinct granules by a neutrophil occurs
at different stages during the inflammatory process (26), so al-
though contained within the one cell, both the serine pro-
teases and their specific inhibitors may be released separately.
Alternatively, serpins may be constitutively secreted with the
proteases remaining sequestered in granules.
In conclusion, our study is the first to suggest a novel role
of serpina1 and serpina3 proteins in regulating the homeosta-
sis of the hematopoietic microenvironment, which ulti-
mately determines the fate of hematopoietic stem cells. This
conclusion is strengthened by other studies using genetic
linkage analysis showing that the Aat locus containing the
serpina1 genes, is significantly linked to BM cellularity in in-
bred mouse strains (40). As reported previously, many
proteoglycans (41), extracellular matrix proteins (42–44),
cytokines, and chemokines (45, 46) expressed in the BM
hematopoietic microenvironment and playing a major role
in determining the fate of hematopoietic stem cells, are sub-
strates of the neutrophil serine proteases that these serpins in-
hibit. Similarly, an earlier report has shown that the addition
of either recombinant human SERPINA1 or antileukopro-
teinase to serum-free culture media boosts in vitro prolifera-
tion and survival of HPCs, probably by protecting cytokines
from the proteases released by differentiated leukocytes (47).
Therefore we propose that (a) serpina1 and serpina3 proteins
play a major role in maintaining the molecular and functional
integrity of the BM hematopoietic microenvironment, (b)
the stoichiometric balance between these serpins and neutro-
phil serine proteases is inverted locally in the BM during sys-
temic administration of G-CSF or chemotherapy, and (c) the
reversal of the serpin–protease balance allows proteases to
evade their naturally occurring inhibitors, accumulate in ac-
tive form and to contribute to the mobilization of HPCs.
MATERIALS AND METHODS
Mobilization of mice, tissue collection, and clonogenic assays.  All
procedures on animals have been approved by the Animal Experimentation
Ethics Committee of the Peter MacCallum Cancer Centre. Male 10–12-
wk-old BALB/c mice were injected with 125  g/kg recombinant human
G-CSF (Neupogen Filgastrim; Amgen) twice daily (days 0–5) or an equal
volume of saline (control mice). Mice were harvested at days 2, 4, and 6 af-
ter G-CSF injection or allowed to rest and harvested at days 8 and 10. Cy-
clophosphamide-treated mice received a single intraperitoneal injection of
200 mg/kg CY (Amersham Biosciences) on day 0.
Peripheral blood was collected in EDTA. Plasma was separated and red
cells lysed with 10 mM NaHCO3, pH 7.4, and 150 mM NH4Cl. Nucle-
ated cells were plated in double-layer nutrient agar clonogenic cultures
(1,500 cells/dish) in the presence human IL-1 , mouse IL-3, mouse CSF-1,
and rat KIT ligand as described previously (9). Colonies were scored after a
2-wk culture at 37 C in the presence of 5% O2, 10% CO2, and 85% N2.
The BM content of one femur from each mouse was flushed into 1 ml
PBS on ice. After centrifugation for 5 min at 400 g, the supernatant fraction
(BM extracellular fluid) was removed and used directly in Western blots or
for the digestion of recombinant human VCAM-1. The BM cell pellet, as
well as the liver and spleen were used for RNA extraction, immunostaining
and cell sorting, or to generate frozen sections.
Flow cytometry and cell sorting.  Bone marrow and spleen cells were
stained using 1  g/ml of directly conjugated mAb (BD Biosciences) for
myeloid cells (Gr-1-FITC and CD11b-PE), for B lymphocytes (B220-PE),
for T lymphocytes (mix of CD3-FITC, CD4-FITC, CD5-FITC, and
CD8a-FITC), and for total hematopoietic cells (CD45-PE). Cells positive
for each category were sorted and RNA extracted as described below.
RNA extraction and quantitative real-time RT-PCR.  Total RNA
was extracted using Trizol (Invitrogen). After DNase treatment and reverse
transcription using random hexamers, quantitative real-time PCR with SYBR
green (ABI Systems) was performed after manufacturer’s instructions using the
oligonucleotide combinations shown in Table I. RNA levels were standard-
ized by parallel RT-PCRs using primers to two different house-keeping
genes, vimentin (a cytoskeletal protein, forward primer 5 -CACCCTGCA-
GTCATTCAGACA-3 ; and reverse 5 -GATTCCACTTTCCGTTCAA-
GGT-3 ) and  2-microglobulin (forward primer 5 -TTCACCCCCACT-
GAGACTGAT and reverse 5 -GTCTTGGGCTCGGCCATA-3 ). Additional
RT-PCRs for the serine proteases NE (forward primer 5 -ACCCTCAT-
TGCCAGGAACTTC-3  and reverse 5 -CCTGCACTGACCGGAAA-
TTT-3 ), CG (forward primer 5 -AGGCAGGGAAGATCATTGGA-3  and
reverse 5 -TGGATCAGAAGAAATGCCATGT-3 ) as well as VCAM-1
(forward primer 5 -CTGGGAAGCTGGAACGAAGTA-3  and reverse 5 -
GCCACTGAATTGAATCTCTGGAT-3 ) and CXCR4 (forward primer
5 -GGCTGACTGGTACTTTGGGAAA-3  and reverse 5 -CCGGTCCA-
GGCTGATGAA-3 ) were also performed. A PCR from each sample before
reverse transcription was also performed to confirm the absence of contaminat-
ing genomic DNA.JEM VOL. 201, April 4, 2005 1087
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VCAM-1 cleavage and immunoblotting.  BM extracellular fluids col-
lected from three mice at day 4 of G-CSF–induced mobilization were
pooled and mixed with an equal volume (10  l) of either pooled BM fluids
from three nonmobilized mice or with PBS. Where indicated, protease in-
hibitors were added at the following concentrations: 1 mg/ml human  1-
antitrypsin (Sigma-Aldrich), 1  M BB-94/Batimastat (British Biotech Phar-
maceuticals), 1 mM O-phenantroline. After a 20-min incubation at room
temperature, 10 ng recombinant human VCAM-1 (98-kD glycosylated ex-
tracellular domain; R&D Systems) was added and the mixture reincubated
at 37 C for 20 min. An equal volume of loading buffer (125 mM Tris-HCl,
pH6.8, 20% glycerol, 2% SDS) was then added and samples boiled for 3
min, before separation by electrophoresis on 10% SDS-PAGE and transfer
onto nitrocellulose membrane. Membranes were immunoblotted using a
goat anti–human VCAM-1 antibody as described previously (9, 10).
Immunoblotting for serpina1 and  2-macroglobulin, and measure-
ments of serpina1 concentration.  10  l aliquots of pooled BM extra-
cellular fluids at indicated time-points of G-CSF or saline administration
were mixed with an equal volume of loading buffer with 10 mM dithio-
threitol, boiled for 3 min, and separated by electrophoresis on 10% SDS-
PAGE. After transfer onto nitrocellulose membranes and blocking in
Odyssey blocking buffer, membranes were incubated for 1 h with an
anti–human  1-antitrypsin (SERPINA1) Ab cross-reacting with mouse
serpina1 diluted 1/3,000 in Odyssey blocking buffer with 0.5% Tween
20. After extensive washes with PBST, membranes were incubated with a
1/3,000 dilution of Alexa Fluor 680–conjugated goat anti–rabbit IgG
(Molecular Probes). Visualization and quantification were performed on
the Odyssey Infrared Imaging System (LI-COR Biosciences) equipped
with two solid phase lasers at 680 and 800 nm with a resolution of 169
 m. The integrated intensity of the serpina1 band in the samples was
compared with that of mouse plasma serpina1 and the moles per femur
calculated, assuming the concentration of murine serpina1 in blood to be
the same as in humans, 1.5 mg/ml (28), with a molecular weight of
53,000. Some experiments were performed with BM extracellular fluids
from three individual mice from each time-point group and average con-
centration   SD were calculated.
Immunoblotting for  2-macroglobulin were performed by incubating
the membranes with a 1/3,000 dilution of a rabbit anti–human  2-macro-
globulin (Sigma-Aldrich) followed by an incubation with a 1/10,000 dilu-
tion of a horseradish peroxidase–conjugated donkey F(ab) 2 anti–rabbit
IgG (Jackson ImmunoResearch Laboratories). Blots were revealed by en-
hanced chemoluminescence.
Measurement of protease catalytic activity.  The concentrations of
active NE and CG in BM extracellular fluids were measured using the
chromogenic substrates methyl-O-succinyl (MetOSuc)–Ala-Ala-Pro-Val–
paranitroanilide (pNA) and Suc-Ala-Ala-Pro-Phe-pNA (Calbiochem-Nova-
biochem) as described previously (9, 10). Measurements were calibrated us-
ing serial dilutions of purified human NE and CG (Elastin Products) and
molar concentrations were calculated using molecular weight of 30,000 and
29,000 for murine NE and CG, respectively.
Immunohistochemistry.  Frozen sections of mouse liver and spleen
were air dried and then fixed for 30 min in methanol containing 0.3%
H2O2 to destroy endogenous peroxidases. Slides were then blocked in 4 
SSC containing 5% BSA, 5% skim milk powder, and 0.05% Triton X-100
for 2 h before incubation with either 25  g/ml purified rabbit anti–human
 1-antitrypsin or nonimmune-purified rabbit IgG in PBST with 5% skim
milk and 5% BSA overnight at 4 C. After extensive washes, slides were in-
cubated with a 1/500 dilution of horseradish peroxidase–conjugated don-
key F(ab) 2 anti–rabbit IgG with minimal cross-reactivity to mouse pro-
teins for 2 h at room temperature, and then washed. Staining was revealed
using 0.5 mg/ml 3,3  diaminobenzidine in 50 mM Tris-HCl, pH 7.4, 0.3%
H2O2 before counterstaining with hematoxylin and mounting with Aqua-
mount (BDH).
For BM wax-embedded sections, femoral BM was fixed by perfusing
0.05% glutaraldehyde, 2% paraformaldehyde into the descending femoral
aorta and femurs processed exactly as described by Nilsson et al. (48). Lon-
gitudinal 3.5- m sections were cut, dewaxed in xylene, and then rehy-
drated using progressive baths from ethanol to water. After antigen retrieval
(12 min boiling in 10 mM sodium citrate, pH 6.0), endogenous peroxidase
elimination and antigen labeling were performed as described above.
Statistics.  Levels of significance were calculated using the nonparametric
Mann-Whitney test.
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